<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7472261\results\search\testTrace\results.xml">
  <result pre="of the integrase strand transfer inhibitor (INSTI) class for the" exact="treatment" post="of HIV-infection has pointed to the importance of analyzing"/>
  <result pre="drug resistance (DR). In this study, we have described the" exact="prevalence" post="of INSTI DR in a Russian cohort and the"/>
  <result pre="of ART-naÃ¯ve patients and among 2.7% of INSTI-naÃ¯ve patients. The" exact="prevalence" post="of 12 polymorphic mutations was significantly different between sub-subtypes"/>
  <result pre="country [1]. Advances in combination antiretroviral therapy (cART) have improved" exact="treatment" post="effectiveness for people living with HIV, increasing life expectancy"/>
  <result pre="of antiretroviral drugs is the latest to be approved for" exact="treatment" post="and is the favored class recommended by different international"/>
  <result pre="favored class recommended by different international guidelines, including the Russian" exact="treatment" post="guidelines since 2017, as part of first-line treatment and"/>
  <result pre="the Russian treatment guidelines since 2017, as part of first-line" exact="treatment" post="and salvage regimens [2,3,4,5,6]. Both clinical trials and real-life"/>
  <result pre="approved by the Food and Drug Administration (FDA) for the" exact="treatment" post="of HIV infection: Raltegravir (RAL), elvitegravir (EVG), dolutegravir (DTG),"/>
  <result pre="(BIC). RAL was the first INSTI drug approved for the" exact="treatment" post="of HIV-infected patients in Russia in 2008, followed by"/>
  <result pre="Drugs guidelines and have been entered as the preferred first-line" exact="treatment" post="regimen [6]. Another INSTI, cabotegravir (CAB), is the newest"/>
  <result pre="and as an oral tablet for daily use for the" exact="treatment" post="and prevention of HIV-1 infection, and it is currently"/>
  <result pre="these patients were all from Russia and had an HIV" exact="infection" post="with subtype A and the L74I mutation before the"/>
  <result pre="infection with subtype A and the L74I mutation before the" exact="treatment" post="initiation [15]. The efficacy outcomes in this study were"/>
  <result pre="similar to those of the ATLAS study, which had 2" exact="treatment" post="experience participants with the L74I mutation from the Russian"/>
  <result pre="in Russia and the former Soviet Union (FSU) countries, the" exact="prevalence" post="of this mutation varied from 93% to 100% [18,19,20,21]."/>
  <result pre="describe INSTI resistance profiles among INSTI-naÃ¯ve patients, to analyze the" exact="prevalence" post="of naturally occurring polymorphisms and genetic barriers, and also"/>
  <result pre="(95% HPD: 1989â€&quot;2003). tMRCA is considered the approximate time of" exact="infection" post="of the potential founder of the sub-subtype A6 epidemic,"/>
  <result pre="data about features of genetic variants and virological outcomes of" exact="treatment" post="in these patients. In this study, we have described"/>
  <result pre="data suggest that the implementation of INSTI drugs for the" exact="treatment" post="of HIV-infected ARV-naÃ¯ve and ARV-experienced patients in Russia will"/>
  <result pre="Our data have added to the overall understanding of the" exact="prevalence" post="of natural polymorphisms in A6 sub-subtype infections [18,19,20,21]. Overall,"/>
  <result pre="and V201I) were described as INSTI resistant [7,9,11,23,24,25,26,33,36,49,50,51,52]. Remarkably, the" exact="prevalence" post="of 12 polymorphic mutations (K14R, R20K, L74I, S119P, T124S,"/>
  <result pre="https://www.mdpi.com/1999-4915/12/8/838/s1, Table S1: Characteristics of the patients, Table S2: The" exact="prevalence" post="of integrase highly polymorphic mutations in A1 and A6"/>
  <result pre="and A6 viral clades in treatment-naÃ¯ve patients, Table S3: The" exact="prevalence" post="of codons in sequences A1, A6, and B and"/>
  <result pre="Infection in AdultsJAMA201832037939610.1001/jama.2018.843130043070 6.PokrovskyV.YurinO.KravchenkoA.BelyaevaV.ErmakT.KanestriV.ShahgildyanV.KozyrinaN.BuravtsovaV.NarsiyaR.et al.National recommendations for dispensary observation and" exact="treatment" post="of HIV patients. Epidemiology and Infectious DiseasesTop. Issue20184184 7.AnstettK.BrennerB.G.MesplÃ¨deT.WainbergM.A.HIV"/>
  <result pre="individualsJ. Med Virol.2019912188219410.1002/jmv.2556431389026 53.Ceccherini-SilbersteinF.MaletI.FabeniL.DimonteS.SvicherV.Dâ€™ArrigoR.ArteseA.CostaG.BonoS.AlcaroS.et al.Specific HIV-1 integrase polymorphisms change their" exact="prevalence" post="in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to"/>
  <result pre="of viruses with the L74M mutation. viruses-12-00838-t001_Table 1Table 1 The" exact="prevalence" post="of codons in sequences A1, A6, and B and"/>
 </snippets>
</snippetsTree>
